Topics

CR UK, Novartis, Sixth Element team up for hard to treat cancers

08:05 EDT 24 Oct 2019 | PharmaTimes

The collaboration focuses on the RAS family of genes, which cause more than 30% of all human cancers, including 95% of pancreatic cancers and 45% of colorectal cancers.

Original Article: CR UK, Novartis, Sixth Element team up for hard to treat cancers

NEXT ARTICLE

More From BioPortfolio on "CR UK, Novartis, Sixth Element team up for hard to treat cancers"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Pancreatic Cancer
The pancreas secretes a number of important hormones into the digestive tract and the blood stream. Cancers are most commonly exocrine than endocrine (neuroendocrine) tumors. Functional tumors secrete hormones; Insulinoma, Gastrinoma, Somatostatinoma, VI...